Literature DB >> 17608770

Mechanism of multidrug recognition by MDR1/ABCB1.

Yasuhisa Kimura1, Shin-ya Morita, Michinori Matsuo, Kazumitsu Ueda.   

Abstract

MDR1/ABCB1, a member of the ABC group of proteins, is clinically important because it is not only involved in multidrug resistance in cancer but also affects the pharmacokinetic properties of various drugs. The most puzzling feature of MDR1 is that it recognizes and transports such a wide variety of substrates. In the present review, the function of MDR1 is compared with that of other ABC proteins, particularly MDR2/ABCB4, to understand the mechanism of drug recognition and transport by MDR1. MDR2, the amino acid sequence of which has 86% similarity to that of MDR1, excretes phosphatidylcholine and cholesterol in the presence of bile salts. ABCA1 transfers phospholipids, preferentially phosphatidylcholine, and cholesterol to lipid-free apoA-I to generate pre-beta-HDL, and ABCG1 excretes phospholipids, preferentially sphingomyelin, and cholesterol. Cholesterol also binds directly to MDR1 and modulates substrate recognition by MDR1. Cholesterol may fill the empty space of the drug-binding site and aid the recognition of small drugs, and facilitates the ability of MDR1 to recognize compounds with various structures and molecular weights. Eukaryote ABC proteins may retain similar substrate binding pockets and move bound substrates in an ATP-dependent manner. The prototype of eukaryote ABC proteins might be those involved in membrane lipid transport.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608770     DOI: 10.1111/j.1349-7006.2007.00538.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  38 in total

1.  Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2.

Authors:  Tasha K Ritchie; Hyewon Kwon; William M Atkins
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Antitumor agents. 280. Multidrug resistance-selective desmosdumotin B analogues.

Authors:  Kyoko Nakagawa-Goto; Po-Cheng Chang; Chin-Yu Lai; Hsin-Yi Hung; Tzu-Hsuan Chen; Pei-Chi Wu; Hao Zhu; Alexander Sedykh; Kenneth F Bastow; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2010-09-23       Impact factor: 7.446

Review 3.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Authors:  Lara Milane; Shanthi Ganesh; Shruti Shah; Zhen-Feng Duan; Mansoor Amiji
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

Review 4.  Anaplastic thyroid cancer, tumorigenesis and therapy.

Authors:  J P O'Neill; D Power; C Condron; D Bouchier-Hayes; M Walsh
Journal:  Ir J Med Sci       Date:  2009-08-07       Impact factor: 1.568

Review 5.  On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the "space-time" dimension of MDR.

Authors:  Vasiliki Panagiotopoulou; Giles Richardson; Oliver E Jensen; Cyril Rauch
Journal:  Eur Biophys J       Date:  2009-11-04       Impact factor: 1.733

6.  Genetic polymorphisms and multiple myeloma risk: a meta-analysis.

Authors:  Pengcheng Zhang; Bing Liu
Journal:  Ann Hematol       Date:  2020-03-11       Impact factor: 3.673

Review 7.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

8.  ATP-binding cassette transporter A1: A promising therapy target for prostate cancer.

Authors:  Ting Xiong; Gang Xu; Xue-Long Huang; Kai-Qiang Lu; Wei-Quan Xie; Kai Yin; Jian Tu
Journal:  Mol Clin Oncol       Date:  2017-11-15

9.  Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.

Authors:  Athina Giannoudis; Andrea Davies; Claire M Lucas; Robert J Harris; Munir Pirmohamed; Richard E Clark
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

10.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.